Creative Medical Technology Holdings (CELZ) EBITDA (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly EBITDA of -$1.5 million for Q1 2026, up 12.12% year-over-year from -$1.3 million in Q1 2025, and up 25.01% quarter-over-quarter from -$1.9 million in Q4 2025.
Creative Medical Technology Holdings (CELZ) EBITDA (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported EBITDA for 17 consecutive years, with -$1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 12.12% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$5.9 million (up 5.41% YoY), while the FY2025 annual figure was -$6.1 million, down 6.95% from the prior year.
- EBITDA rose to -$1.5 million in Q1 2026 per CELZ's latest filing, from -$1.9 million in the prior quarter.
- Across five years, EBITDA topped out at -$1.0 million in Q3 2022 and bottomed at -$6.3 million in Q4 2022.
- Historically, EBITDA has averaged -$1.7 million across 5 years, with a median of -$1.5 million in 2026.
- Annual changes were most pronounced in 2022 — EBITDA plunged 326.28% — and 2023, when it soared 71.78%.
- Creative Medical Technology Holdings' EBITDA stood at -$6.3 million in 2022, then jumped by 71.78% to -$1.8 million in 2023, then slipped by 6.43% to -$1.9 million in 2024, then fell by 3.18% to -$1.9 million in 2025, then climbed by 25.01% to -$1.5 million in 2026.
- Business Quant data shows CELZ's EBITDA at -$1.5 million in Q1 2026, -$1.9 million in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | -1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.56 Mn |
| Mar 31, 2026 | -1.46 Mn |
| Dec 31, 2025 | -1.95 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Jun 30, 2025 | -1.26 Mn |
| Mar 31, 2025 | -1.66 Mn |
| Dec 31, 2024 | -1.89 Mn |
| Sep 30, 2024 | -1.11 Mn |
| Jun 30, 2024 | -1.63 Mn |
| Mar 31, 2024 | -1.12 Mn |
| Dec 31, 2023 | -1.77 Mn |
| Sep 30, 2023 | -1.54 Mn |
| Jun 30, 2023 | -1.19 Mn |
| Mar 31, 2023 | -1.11 Mn |
| Dec 31, 2022 | -6.28 Mn |
| Sep 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -1.79 Mn |
| Mar 31, 2022 | -1.15 Mn |
| Dec 31, 2021 | -1.47 Mn |
| Sep 30, 2021 | -833,436.00 |